160 related articles for article (PubMed ID: 21980378)
1. Proteomic analysis of ovarian cancer proximal fluids: validation of elevated peroxiredoxin 1 in patient peripheral circulation.
Hoskins ER; Hood BL; Sun M; Krivak TC; Edwards RP; Conrads TP
PLoS One; 2011; 6(9):e25056. PubMed ID: 21980378
[TBL] [Abstract][Full Text] [Related]
2. Proteomic analysis of non-small cell lung cancer tissue interstitial fluids.
Li S; Wang R; Zhang M; Wang L; Cheng S
World J Surg Oncol; 2013 Aug; 11():173. PubMed ID: 23914992
[TBL] [Abstract][Full Text] [Related]
3. Screening and identification of biomarkers in ascites related to intrinsic chemoresistance of serous epithelial ovarian cancers.
Huang H; Li Y; Liu J; Zheng M; Feng Y; Hu K; Huang Y; Huang Q
PLoS One; 2012; 7(12):e51256. PubMed ID: 23251472
[TBL] [Abstract][Full Text] [Related]
4. Early inflammatory response in epithelial ovarian tumor cyst fluids.
Kristjánsdóttir B; Partheen K; Fung ET; Yip C; Levan K; Sundfeldt K
Cancer Med; 2014 Oct; 3(5):1302-12. PubMed ID: 24947406
[TBL] [Abstract][Full Text] [Related]
5. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
[TBL] [Abstract][Full Text] [Related]
6. Ovarian cancer circulating extracelluar vesicles promote coagulation and have a potential in diagnosis: an iTRAQ based proteomic analysis.
Zhang W; Peng P; Ou X; Shen K; Wu X
BMC Cancer; 2019 Nov; 19(1):1095. PubMed ID: 31718609
[TBL] [Abstract][Full Text] [Related]
7. The ascites N-glycome of epithelial ovarian cancer patients.
Biskup K; Braicu EI; Sehouli J; Tauber R; Blanchard V
J Proteomics; 2017 Mar; 157():33-39. PubMed ID: 28188862
[TBL] [Abstract][Full Text] [Related]
8. Increased WD-repeat containing protein 1 in interstitial fluid from ovarian carcinomas shown by comparative proteomic analysis of malignant and healthy gynecological tissue.
Haslene-Hox H; Oveland E; Woie K; Salvesen HB; Wiig H; Tenstad O
Biochim Biophys Acta; 2013 Nov; 1834(11):2347-59. PubMed ID: 23707566
[TBL] [Abstract][Full Text] [Related]
9. Profiling signatures of ovarian cancer tumour suppression using 2D-DIGE and 2D-LC-MS/MS with tandem mass tagging.
Sinclair J; Metodieva G; Dafou D; Gayther SA; Timms JF
J Proteomics; 2011 Apr; 74(4):451-65. PubMed ID: 21237297
[TBL] [Abstract][Full Text] [Related]
10. Quantitative assessment of serum heat shock protein 27 for the diagnosis of epithelial ovarian cancer using targeted proteomics coupled with immunoaffinity enrichment.
Yang T; Xu P; Gu L; Xu Z; Ge W; Li Q; Xu F
Clin Chim Acta; 2019 Feb; 489():96-102. PubMed ID: 30502327
[TBL] [Abstract][Full Text] [Related]
11. Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study.
Brunette LL; Mhawech-Fauceglia PY; Ji L; Skeate JG; Brand HE; Lawrenson K; Walia S; Chiriva-Internati M; Groshen S; Roman LD; Kast WM; Da Silva DM
BMC Cancer; 2018 Oct; 18(1):970. PubMed ID: 30309325
[TBL] [Abstract][Full Text] [Related]
12. Discovery of serum biomarkers implicated in the onset and progression of serous ovarian cancer in a rat model using iTRAQ technique.
Huang Y; Zhang X; Jiang W; Wang Y; Jin H; Liu X; Xu C
Eur J Obstet Gynecol Reprod Biol; 2012 Nov; 165(1):96-103. PubMed ID: 22818854
[TBL] [Abstract][Full Text] [Related]
13. Crosstalk between TEMs and endothelial cells modulates angiogenesis and metastasis via IGF1-IGF1R signalling in epithelial ovarian cancer.
Wang X; Zhu Q; Lin Y; Wu L; Wu X; Wang K; He Q; Xu C; Wan X; Wang X
Br J Cancer; 2017 Oct; 117(9):1371-1382. PubMed ID: 28898232
[TBL] [Abstract][Full Text] [Related]
14. In-depth proteomics of ovarian cancer ascites: combining shotgun proteomics and selected reaction monitoring mass spectrometry.
Elschenbroich S; Ignatchenko V; Clarke B; Kalloger SE; Boutros PC; Gramolini AO; Shaw P; Jurisica I; Kislinger T
J Proteome Res; 2011 May; 10(5):2286-99. PubMed ID: 21491939
[TBL] [Abstract][Full Text] [Related]
15. Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer.
Kolomeyevskaya N; Eng KH; Khan AN; Grzankowski KS; Singel KL; Moysich K; Segal BH
Gynecol Oncol; 2015 Aug; 138(2):352-7. PubMed ID: 26001328
[TBL] [Abstract][Full Text] [Related]
16. Assessment of buffer systems for harvesting proteins from tissue interstitial fluid for proteomic analysis.
Teng PN; Rungruang BJ; Hood BL; Sun M; Flint MS; Bateman NW; Dhir R; Bhargava R; Richard SD; Edwards RP; Conrads TP
J Proteome Res; 2010 Aug; 9(8):4161-9. PubMed ID: 20518575
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor expression correlates with serum CA125 and represents a useful tool in prediction of refractoriness to platinum-based chemotherapy and ascites formation in epithelial ovarian cancer.
Masoumi-Moghaddam S; Amini A; Wei AQ; Robertson G; Morris DL
Oncotarget; 2015 Sep; 6(29):28491-501. PubMed ID: 26143638
[TBL] [Abstract][Full Text] [Related]
18. Upregulated CDK16 Expression in Serous Epithelial Ovarian Cancer Cells.
Zhou Q; Yu Y
Med Sci Monit; 2015 Nov; 21():3409-14. PubMed ID: 26546806
[TBL] [Abstract][Full Text] [Related]
19. [Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].
Wu WJ; Wang Q; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2016 Jul; 51(7):515-23. PubMed ID: 27465871
[TBL] [Abstract][Full Text] [Related]
20. Identification of proteomic and metabolic signatures associated with chemoresistance of human epithelial ovarian cancer.
Wu W; Wang Q; Yin F; Yang Z; Zhang W; Gabra H; Li L
Int J Oncol; 2016 Oct; 49(4):1651-65. PubMed ID: 27511453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]